New York City-based Mount Sinai and Memorial Sloan Kettering Cancer Center researchers identified therapies that can help patients with recurring blood cancer multiple myeloma who have already tried one form of CAR-T therapy, Science Daily reported Nov. 4.
The study, published in Blood, followed a large group of multiple myeloma patients whose cancer returned after CAR-T therapy, an immunotherapy. Researchers found other therapies that engage T cells, such as bispecific antibodies and other types of CAR-T cell therapy, led to longer recessions in patients' cancer.
"The findings of this study will serve as a benchmark for future prospective clinical studies that intend to improve the outcomes of patients who progress after CAR-T," senior author Samir Parekh, MD, director of translational research in multiple myeloma and co-leader of the Cancer Clinical Investigation program at the Tisch Cancer Institute at the Icahn School of Medicine at Mount Sinai, said. "This is the first study to report outcomes of different therapeutic options given to a large cohort of patients who relapsed after anti-BCMA CAR-T therapy. This is one of the most urgent and unmet needs in myeloma patients and, therefore, of great interest to the hematology community."